Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Reply to Dee, and Johnson and Folayan.

Lelièvre JD.

J Infect Dis. 2019 Aug 30;220(7):1234. doi: 10.1093/infdis/jiz265. No abstract available.

PMID:
31505664
2.

Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination.

Surenaud M, Montes M, Lindestam Arlehamn CS, Sette A, Banchereau J, Palucka K, Lelièvre JD, Lacabaratz C, Lévy Y.

PLoS Pathog. 2019 Sep 9;15(9):e1008011. doi: 10.1371/journal.ppat.1008011. eCollection 2019 Sep.

3.

Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials.

Durier C, Desaint C, Lelièvre JD, Silbermann B, Pialoux G, Cuzin L, Bonnet B, Poizot-Martin I, Bouakane A, Paul C, Grabar S, Spire B, Meyer L, Launay O; ANRS/VRI COHVAC Study Group.

AIDS. 2019 Nov 1;33(13):2061-2071. doi: 10.1097/QAD.0000000000002310.

PMID:
31306171
4.

Proliferative memory SAMHD1low CD4+ T cells harbour high levels of HIV-1 with compartmentalized viral populations.

Hani L, Chaillon A, Nere ML, Ruffin N, Alameddine J, Salmona M, Lopez Zaragoza JL, Smith DM, Schwartz O, Lelièvre JD, Delaugerre C, Lévy Y, Seddiki N.

PLoS Pathog. 2019 Jun 20;15(6):e1007868. doi: 10.1371/journal.ppat.1007868. eCollection 2019 Jun.

5.

Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.

Shafran SD, Di Perri G, Esser S, Lelièvre JD, Parczewski M.

HIV Med. 2019 Jun;20 Suppl 7:1-16. doi: 10.1111/hiv.12755. Review.

PMID:
31099116
6.

Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.

Moore CL, Stöhr W, Crook AM, Richert L, Leliévre JD, Pantaleo G, García F, Vella S, Lévy Y, Thiébaut R, McCormack S.

Lancet HIV. 2019 May;6(5):e334-e340. doi: 10.1016/S2352-3018(19)30082-7.

PMID:
31047670
7.

Early blood transcriptomic signature predicts patients' outcome after out-of-hospital cardiac arrest.

Tissier R, Hocini H, Tchitchek N, Deye N, Legriel S, Pichon N, Daubin C, Hermine O, Carli P, Vivien B, Tréluyer JM, Lefebvre C, Tisserand P, Dubois-Randé JL, Berdeaux A, Ghaleh B, Lelièvre JD, Levy Y, Cariou A.

Resuscitation. 2019 May;138:222-232. doi: 10.1016/j.resuscitation.2019.03.006. Epub 2019 Mar 15.

PMID:
30885824
8.

Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.

Lelièvre JD.

J Infect Dis. 2019 Jul 2;220(Supplement_1):S16-S18. doi: 10.1093/infdis/jiz036.

PMID:
30860581
9.

HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood.

Hocini H, Bonnabau H, Lacabaratz C, Lefebvre C, Tisserand P, Foucat E, Lelièvre JD, Lambotte O, Saez-Cirion A, Versmisse P, Thiébaut R, Lévy Y.

J Virol. 2019 May 1;93(10). pii: e01690-18. doi: 10.1128/JVI.01690-18. Print 2019 May 15.

PMID:
30814287
10.

Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.

Lelièvre JD, Hocqueloux L.

J Infect Dis. 2019 Jul 2;220(Supplement_1):S5-S6. doi: 10.1093/infdis/jiz012.

PMID:
30779842
11.

Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.

Matignon M, Lelièvre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, Peraldi MN, Taburet AM, Saillard J, Delaugerre C, Costagliola D, Assoumou L, Grimbert P; ANRS 153 TREVE study group.

HIV Med. 2019 Mar;20(3):202-213. doi: 10.1111/hiv.12700. Epub 2019 Jan 27.

PMID:
30688008
12.

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

Eron JJ Jr, Lelievre JD, Kalayjian R, Slim J, Wurapa AK, Stephens JL, McDonald C, Cua E, Wilkin A, Schmied B, McKellar M, Cox S, Majeed SR, Jiang S, Cheng A, Das M, SenGupta D.

Lancet HIV. 2018 Dec 13. pii: S2352-3018(18)30296-0. doi: 10.1016/S2352-3018(18)30296-0. [Epub ahead of print]

PMID:
30555051
13.

Development of high throughput screening methods for inhibitors of ClpC1P1P2 from Mycobacteria tuberculosis.

Fraga H, Rodriguez B, Bardera A, Cid C, Akopian T, Kandror O, Park A, Colmenarejo G, Lelievre J, Goldberg A.

Anal Biochem. 2019 Feb 15;567:30-37. doi: 10.1016/j.ab.2018.12.004. Epub 2018 Dec 10.

14.

Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial.

Palich R, Ghosn J, Chaillon A, Boilet V, Nere ML, Chaix ML, Delobel P, Molina JM, Lucht F, Bouchaud O, Rieux V, Thiebaut R, Levy Y, Delaugerre C, Lelievre JD; VRI02/ANRS149 LIGHT Vaccine Trial Group.

AIDS. 2019 Feb 1;33(2):279-284. doi: 10.1097/QAD.0000000000002058.

PMID:
30325777
15.

Interview With Jean-Daniel Lelièvre, PU-PH, Head of the Research Clinic of the VRI (Vaccine Research Institute).

Lelievre JD, Ollivier-Yaniv C.

J Acquir Immune Defic Syndr. 2018 Oct 1;79 Suppl 1:S8-S12. doi: 10.1097/QAI.0000000000001813. No abstract available.

PMID:
30222700
16.

Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach.

Soto R, Perez-Herran E, Rodriguez B, Duma BM, Cacho-Izquierdo M, Mendoza-Losana A, Lelievre J, Aguirre DB, Ballell L, Cox LR, Alderwick LJ, Besra GS.

Sci Rep. 2018 Aug 23;8(1):12664. doi: 10.1038/s41598-018-31157-3.

17.

Author Correction: Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening.

Machutta CA, Kollmann CS, Lind KE, Bai X, Chan PF, Huang J, Ballell L, Belyanskaya S, Besra GS, Barros-Aguirre D, Bates RH, Centrella PA, Chang SS, Chai J, Choudhry AE, Coffin A, Davie CP, Deng H, Deng J, Ding Y, Dodson JW, Fosbenner DT, Gao EN, Graham TL, Graybill TL, Ingraham K, Johnson WP, King BW, Kwiatkowski CR, Lelièvre J, Li Y, Liu X, Lu Q, Lehr R, Mendoza-Losana A, Martin J, McCloskey L, McCormick P, O'Keefe HP, O'Keeffe T, Pao C, Phelps CB, Qi H, Rafferty K, Scavello GS, Steiginga MS, Sundersingh FS, Sweitzer SM, Szewczuk LM, Taylor A, Fern Toh M, Wang J, Wang M, Wilkins DJ, Xia B, Yao G, Zhang J, Zhou J, Donahue CP, Messer JA, Holmes D, Arico-Muendel CC, Pope AJ, Gross JW, Evindar G.

Nat Commun. 2018 Jul 13;9:16227. doi: 10.1038/ncomms16227.

18.

Progress towards obtaining an HIV cure: slow but sure.

Henrich TJ, Lelièvre JD.

Curr Opin HIV AIDS. 2018 Sep;13(5):381-382. doi: 10.1097/COH.0000000000000492. No abstract available.

PMID:
29965799
19.

Differential correlations between changes to glutathione redox state, protein ubiquitination, and stress-inducible HSPA chaperone expression after different types of oxidative stress.

Girard PM, Peynot N, Lelièvre JM.

Cell Stress Chaperones. 2018 Sep;23(5):985-1002. doi: 10.1007/s12192-018-0909-y. Epub 2018 May 12.

20.

Accelerating Early Antituberculosis Drug Discovery by Creating Mycobacterial Indicator Strains That Predict Mode of Action.

Boot M, Commandeur S, Subudhi AK, Bahira M, Smith TC 2nd, Abdallah AM, van Gemert M, Lelièvre J, Ballell L, Aldridge BB, Pain A, Speer A, Bitter W.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00083-18. doi: 10.1128/AAC.00083-18. Print 2018 Jul.

21.

Early Antiretroviral Therapy Preserves Functional Follicular Helper T and HIV-Specific B Cells in the Gut Mucosa of HIV-1-Infected Individuals.

Planchais C, Hocqueloux L, Ibanez C, Gallien S, Copie C, Surenaud M, Kök A, Lorin V, Fusaro M, Delfau-Larue MH, Lefrou L, Prazuck T, Lévy M, Seddiki N, Lelièvre JD, Mouquet H, Lévy Y, Hüe S.

J Immunol. 2018 May 15;200(10):3519-3529. doi: 10.4049/jimmunol.1701615. Epub 2018 Apr 9.

22.

The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from Mycobacterium tuberculosis.

Weinhäupl K, Brennich M, Kazmaier U, Lelievre J, Ballell L, Goldberg A, Schanda P, Fraga H.

J Biol Chem. 2018 Jun 1;293(22):8379-8393. doi: 10.1074/jbc.RA118.002251. Epub 2018 Apr 9.

23.

Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets.

Trofimov V, Kicka S, Mucaria S, Hanna N, Ramon-Olayo F, Del Peral LV, Lelièvre J, Ballell L, Scapozza L, Besra GS, Cox JAG, Soldati T.

Sci Rep. 2018 Mar 2;8(1):3939. doi: 10.1038/s41598-018-22228-6.

24.

High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds.

Zampieri M, Szappanos B, Buchieri MV, Trauner A, Piazza I, Picotti P, Gagneux S, Borrell S, Gicquel B, Lelievre J, Papp B, Sauer U.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaal3973. doi: 10.1126/scitranslmed.aal3973.

25.

A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK.

Chiarelli LR, Mori G, Orena BS, Esposito M, Lane T, de Jesus Lopes Ribeiro AL, Degiacomi G, Zemanová J, Szádocka S, Huszár S, Palčeková Z, Manfredi M, Gosetti F, Lelièvre J, Ballell L, Kazakova E, Makarov V, Marengo E, Mikusova K, Cole ST, Riccardi G, Ekins S, Pasca MR.

Sci Rep. 2018 Feb 16;8(1):3187. doi: 10.1038/s41598-018-21614-4.

26.

Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC).

Preau M, Doumergue M, Protiere C, Goujard C, Mora M, Meyer L, Lelievre JD, Raffi F, Spire B, Lambotte O, Suzan-Monti M.

AIDS Care. 2018 Jul;30(7):914-920. doi: 10.1080/09540121.2018.1426825. Epub 2018 Jan 18.

PMID:
29347826
27.

Hospitalization of HIV positive patients: Significant demand affecting all hospital sectors.

Seng R, Mutuon P, Riou J, Duvivier C, Weiss L, Lelievre JD, Meyer L, Vittecoq D, Zak Dit Zbar O, Frenkiel J, Frank-Soltysiak M, Boue F, Rapp C, Sobel A, Brucker G, Goujard C, Salmon D; COREVIH.

Rev Epidemiol Sante Publique. 2018 Feb;66(1):7-17. doi: 10.1016/j.respe.2017.08.002. Epub 2017 Dec 10.

PMID:
29233572
28.

Endoperoxide-based compounds: cross-resistance with artemisinins and selection of a Plasmodium falciparum lineage with a K13 non-synonymous polymorphism.

Paloque L, Witkowski B, Lelièvre J, Ouji M, Ben Haddou T, Ariey F, Robert A, Augereau JM, Ménard D, Meunier B, Benoit-Vical F.

J Antimicrob Chemother. 2018 Feb 1;73(2):395-403. doi: 10.1093/jac/dkx412.

PMID:
29177421
29.

Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.

Wilson CR, Gessner RK, Moosa A, Seldon R, Warner DF, Mizrahi V, Soares de Melo C, Simelane SB, Nchinda A, Abay E, Taylor D, Njoroge M, Brunschwig C, Lawrence N, Boshoff HIM, Barry CE 3rd, Sirgel FA, van Helden P, Harris CJ, Gordon R, Ghidelli-Disse S, Pflaumer H, Boesche M, Drewes G, Sanz O, Santos G, Rebollo-Lopez MJ, Urones B, Selenski C, Lafuente-Monasterio MJ, Axtman M, Lelièvre J, Ballell L, Mueller R, Street LJ, Ghorpade SR, Chibale K.

J Med Chem. 2017 Dec 28;60(24):10118-10134. doi: 10.1021/acs.jmedchem.7b01347. Epub 2017 Dec 7.

30.

Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients.

Thiébaut R, Hue S, Le Marec F, Lelièvre JD, Dupon M, Foucat E, Lazaro E, Dabis F, Duffau P, Wittkop L, Surenaud M, Pellegrin I, Lacabaratz C, Bonnet F, Lévy Y; ANRS CO3 Aquitaine Cohort.

AIDS. 2017 Nov 13;31(17):2355-2365. doi: 10.1097/QAD.0000000000001628.

PMID:
29068834
31.

Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach.

Mugumbate G, Mendes V, Blaszczyk M, Sabbah M, Papadatos G, Lelievre J, Ballell L, Barros D, Abell C, Blundell TL, Overington JP.

Front Pharmacol. 2017 Sep 26;8:681. doi: 10.3389/fphar.2017.00681. eCollection 2017.

32.

Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.

Narbey D, Habibi A, Chadebech P, Mekontso-Dessap A, Khellaf M, Lelièvre JD, Godeau B, Michel M, Galactéros F, Djoudi R, Bartolucci P, Pirenne F.

Am J Hematol. 2017 Dec;92(12):1340-1348. doi: 10.1002/ajh.24908. Epub 2017 Oct 31.

33.

Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients.

Parpaleix A, Boyer L, Wiedemann A, Lacabaratz C, Margarit L, Enouf V, Le Corvoisier P, Lino A, Covali-Noroc A, Housset B, Chouaid C, Maitre B, Lévy Y, Lelièvre JD, Adnot S.

J Allergy Clin Immunol. 2017 Dec;140(6):1754-1757.e6. doi: 10.1016/j.jaci.2017.07.038. Epub 2017 Sep 7. No abstract available.

PMID:
28889955
34.

Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.

Surenaud M, Lacabaratz C, Zurawski G, Lévy Y, Lelièvre JD.

Expert Rev Vaccines. 2017 Oct;16(10):955-972. doi: 10.1080/14760584.2017.1374182. Review.

PMID:
28879788
35.

Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening.

Machutta CA, Kollmann CS, Lind KE, Bai X, Chan PF, Huang J, Ballell L, Belyanskaya S, Besra GS, Barros-Aguirre D, Bates RH, Centrella PA, Chang SS, Chai J, Choudhry AE, Coffin A, Davie CP, Deng H, Deng J, Ding Y, Dodson JW, Fosbenner DT, Gao EN, Graham TL, Graybill TL, Ingraham K, Johnson WP, King BW, Kwiatkowski CR, Lelièvre J, Li Y, Liu X, Lu Q, Lehr R, Mendoza-Losana A, Martin J, McCloskey L, McCormick P, O'Keefe HP, O'Keeffe T, Pao C, Phelps CB, Qi H, Rafferty K, Scavello GS, Steiginga MS, Sundersingh FS, Sweitzer SM, Szewczuk LM, Taylor A, Toh MF, Wang J, Wang M, Wilkins DJ, Xia B, Yao G, Zhang J, Zhou J, Donahue CP, Messer JA, Holmes D, Arico-Muendel CC, Pope AJ, Gross JW, Evindar G.

Nat Commun. 2017 Jul 17;8:16081. doi: 10.1038/ncomms16081. Erratum in: Nat Commun. 2018 Jul 13;9:16227.

36.

Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine.

Brezar V, Hani L, Surenaud M, Hubert A, Lacabaratz C, Lelièvre JD, Levy Y, Seddiki N.

PLoS Pathog. 2017 Jul 14;13(7):e1006489. doi: 10.1371/journal.ppat.1006489. eCollection 2017 Jul.

37.

A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors.

Esposito M, Szadocka S, Degiacomi G, Orena BS, Mori G, Piano V, Boldrin F, Zemanová J, Huszár S, Barros D, Ekins S, Lelièvre J, Manganelli R, Mattevi A, Pasca MR, Riccardi G, Ballell L, Mikušová K, Chiarelli LR.

ACS Infect Dis. 2017 Jun 9;3(6):428-437. doi: 10.1021/acsinfecdis.7b00006. Epub 2017 May 11.

PMID:
28475832
38.

CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses.

Descours B, Petitjean G, López-Zaragoza JL, Bruel T, Raffel R, Psomas C, Reynes J, Lacabaratz C, Levy Y, Schwartz O, Lelievre JD, Benkirane M.

Nature. 2017 Mar 23;543(7646):564-567. doi: 10.1038/nature21710. Epub 2017 Mar 15. Erratum in: Nature. 2017 Jun 28;546(7660):686.

PMID:
28297712
39.

Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen.

Cox JA, Mugumbate G, Del Peral LV, Jankute M, Abrahams KA, Jervis P, Jackenkroll S, Perez A, Alemparte C, Esquivias J, Lelièvre J, Ramon F, Barros D, Ballell L, Besra GS.

Sci Rep. 2016 Dec 16;6:38986. doi: 10.1038/srep38986.

40.

Successful improvement of Buschke-Löwenstein tumour in an HIV-infected patient with antiretroviral therapy alone.

Grodner C, Henn A, Lelièvre JD, Gallien S.

BMJ Case Rep. 2016 Nov 21;2016. pii: bcr2016217753. doi: 10.1136/bcr-2016-217753.

41.

Regulation of heat-inducible HSPA1A gene expression during maternal-to-embryo transition and in response to heat in in vitro-produced bovine embryos.

Lelièvre JM, Peynot N, Ruffini S, Laffont L, Le Bourhis D, Girard PM, Duranthon V.

Reprod Fertil Dev. 2017 Sep;29(9):1868-1881. doi: 10.1071/RD15504.

PMID:
27851888
42.

Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.

Park Y, Pacitto A, Bayliss T, Cleghorn LA, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M, Donini S, Blundell TL, Ascher DB, Rhee K, Breda A, Zhou N, Dartois V, Jonnala SR, Via LE, Mizrahi V, Epemolu O, Stojanovski L, Simeons F, Osuna-Cabello M, Ellis L, MacKenzie CJ, Smith AR, Davis SH, Murugesan D, Buchanan KI, Turner PA, Huggett M, Zuccotto F, Rebollo-Lopez MJ, Lafuente-Monasterio MJ, Sanz O, Diaz GS, Lelièvre J, Ballell L, Selenski C, Axtman M, Ghidelli-Disse S, Pflaumer H, Bösche M, Drewes G, Freiberg GM, Kurnick MD, Srikumaran M, Kempf DJ, Green SR, Ray PC, Read K, Wyatt P, Barry CE 3rd, Boshoff HI.

ACS Infect Dis. 2017 Jan 13;3(1):18-33. doi: 10.1021/acsinfecdis.6b00103. Epub 2016 Oct 17.

43.

Identification of KasA as the cellular target of an anti-tubercular scaffold.

Abrahams KA, Chung CW, Ghidelli-Disse S, Rullas J, Rebollo-López MJ, Gurcha SS, Cox JA, Mendoza A, Jiménez-Navarro E, Martínez-Martínez MS, Neu M, Shillings A, Homes P, Argyrou A, Casanueva R, Loman NJ, Moynihan PJ, Lelièvre J, Selenski C, Axtman M, Kremer L, Bantscheff M, Angulo-Barturen I, Izquierdo MC, Cammack NC, Drewes G, Ballell L, Barros D, Besra GS, Bates RH.

Nat Commun. 2016 Sep 1;7:12581. doi: 10.1038/ncomms12581.

44.

HIV-1 prophylactic vaccines: state of the art.

Lelièvre JD, Lévy Y.

J Virus Erad. 2016 Jan 1;2(1):5-11. Review.

45.

A novel validated assay to support the discovery of new anti-malarial gametocytocidal agents.

Bahamontes-Rosa N, Gomez-Lorenzo MG, Lelièvre J, Rodriguez Alejandre A, Almela MJ, Lozano S, Herreros E, Gamo FJ.

Malar J. 2016 Jul 22;15(1):385. doi: 10.1186/s12936-016-1429-9.

46.

A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus.

Dupont C, Viljoen A, Dubar F, Blaise M, Bernut A, Pawlik A, Bouchier C, Brosch R, Guérardel Y, Lelièvre J, Ballell L, Herrmann JL, Biot C, Kremer L.

Mol Microbiol. 2016 Aug;101(3):515-29. doi: 10.1111/mmi.13406. Epub 2016 Jun 1.

47.

P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART.

Menkova-Garnier I, Hocini H, Foucat E, Tisserand P, Bourdery L, Delaugerre C, Benne C, Lévy Y, Lelièvre JD.

PLoS Pathog. 2016 Apr 15;12(4):e1005571. doi: 10.1371/journal.ppat.1005571. eCollection 2016 Apr.

48.

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.

Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, García F, Harrer T, Lelievre JD, Frank I, Colin De Verdière N, Yeni GP, Ortega Gonzalez E, Rubio R, Clotet Sala B, DeJesus E, Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L, Bouchaud O, Felizarta F, Meurer A, Raffi F, Esser S, Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M, Collard A, Bourguignon P, Roman F.

Medicine (Baltimore). 2016 Feb;95(6):e2673. doi: 10.1097/MD.0000000000002673.

49.

Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.

Rebollo-Lopez MJ, Lelièvre J, Alvarez-Gomez D, Castro-Pichel J, Martínez-Jiménez F, Papadatos G, Kumar V, Colmenarejo G, Mugumbate G, Hurle M, Barroso V, Young RJ, Martinez-Hoyos M, González del Río R, Bates RH, Lopez-Roman EM, Mendoza-Losana A, Brown JR, Alvarez-Ruiz E, Marti-Renom MA, Overington JP, Cammack N, Ballell L, Barros-Aguire D.

PLoS One. 2015 Dec 7;10(12):e0142293. doi: 10.1371/journal.pone.0142293. eCollection 2015.

50.

A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery.

Almela MJ, Lozano S, Lelièvre J, Colmenarejo G, Coterón JM, Rodrigues J, Gonzalez C, Herreros E.

PLoS One. 2015 Aug 28;10(8):e0135139. doi: 10.1371/journal.pone.0135139. eCollection 2015.

Supplemental Content

Loading ...
Support Center